Loading…
Loading…
Healthcare and technology provide an intriguing contrast. Many healthcare stocks are traditionally known for their more defensive uses in portfolios.
GDOC hits a 52-week high as aging demographics, tech advances and strength from top holding LLY fuel momentum.
Biotech investing may not be the most obvious place for investors to look right now, but factors may be turning in the category's favor. Multiple rate cuts in the back half of 2025 and a friendlier regulatory regime may position biotech investing as a shrewd option to end the year.
Is now the time to consider biotech ETFs? The stars may be aligning for investing in biotech as 2025 draws to a closer, with ETFs a key route into the space.
Active management in ETFs are gaining market share in 2023, as leading managers bring their best ideas into the ETF industry. As of July 31, 169 active ETFs had launched in 2023, comprising nearly 70% of total ETF launches.
Greetings, VettaFi Voices! Now seems like a good time to talk about wrappers and which ones are best for different situations.
With actively managed ETFs, advisors and clients are willing to pay a premium relative to investing in an index-based approach. However, they want to be rewarded.
VettaFi's Equity Symposium is just over a week away and will provide advisors with free access to some of the most important thought leaders in the investment space.
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for GDOC and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.